Crystalline forms of...

Details Crystalline forms of... Crystalline forms of...

2011-05-31

2011-05-31

Anderson, Rebecca L (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S374100

Reexamination Certificate

active

07951833

ABSTRACT:
New crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

REFERENCES:
patent: 2006/0223852 (2006-10-01), Gillespie et al.
patent: 2008/0269288 (2008-10-01), McCoull et al.
patent: 2009/0221663 (2009-09-01), Packer et al.
patent: 2009/0264401 (2009-10-01), Gill et al.
patent: 2009/0306075 (2009-12-01), McCoull et al.
patent: 2009/0312372 (2009-12-01), McCoull et al.
patent: 2010/0022589 (2010-01-01), McCoull et al.
patent: 1889842 (2008-02-01), None
patent: 1894919 (2008-03-01), None
patent: WO 2004/089470 (2004-10-01), None
patent: WO 2005/016877 (2005-02-01), None
patent: WO 2005/108359 (2005-11-01), None
patent: WO 2006/048750 (2006-05-01), None
patent: WO 2006/106054 (2006-10-01), None
patent: WO 2006/113261 (2006-10-01), None
patent: WO 2006/132197 (2006-12-01), None
patent: WO 2006/132436 (2006-12-01), None
patent: WO 2007/052843 (2007-05-01), None
patent: WO 2007/058346 (2007-05-01), None
patent: WO 2008/012532 (2008-01-01), None
patent: WO 2008/053194 (2008-05-01), None
patent: WO 2008/099145 (2008-08-01), None
patent: WO 2008/142986 (2008-11-01), None
patent: WO 2009/010416 (2009-01-01), None
Brittain et al. “Polymorphism in Pharmaceutical Dosage Forms.” Polymorphism in Pharmaceutical Solids XX (Jan. 1999), relevant pages attached.
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Vippagunta et al. Advanced Drug Delivery Reviews 2001, 48, 3-26, abstract.
Blake et al. “Discovery of 3,3-dimethyl-azetidin-2-ones as potent and selective inhibitors of 11β-HSD1” Gordon Research Conference on Medicinal Chemistry, Colby-Sawyer College, New London, NH, USA (Aug. 2007).
Boyle “Recent advances in the discovery of 11b-HSD1 inhibitors” Current Opinion in Drug Discovery and Development 11:495-511 (2008).
deSchoolmeester et al. “An increase in obesity is associated with increased 11βHSD1 activity but not expression in mature human subcutaneous adipocytes” Association for the Study of Obesity (ASO) and Adipose Tissue Discussion Group, Institute of Child Health, London (Nov. 9, 2006).
Jean et al. “Inhibitors of 11â-HSD1: A Potential Treatment for the Metabolic Syndrome” Current Topics in Medicinal Chemistry 8(17): 1508-1523 (2008).
Mayers “11β-hydroxysteroid dehydrogenase type 1: a tale of (fat) mice to men” Abstract and Presentation, Obesity and its Treatment, Society for Medicines Research (Sep. 25, 2008).

Affiliated with

Also associated with

Rating

Crystalline forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2687671